AG
NAMS icon

Algert Global’s NewAmsterdam Pharma NAMS Stock Holding History

Algert Global’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,140
Closed -$329K – 1273
2025
Q2 		$329K Buy
+18,140
New +$331K 0.01% 1013

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Algert Global's NAMS Position: Q3 2025 in Review

Algert Global sold out of NewAmsterdam Pharma (NAMS) in Q3 2025, closing a stake of 18,140 shares — an estimated $329K sold.

Algert Global first reported a position in NAMS in Q2 2025 and held it in 1 quarter. The position peaked at $329K in Q2 2025. 137 funds tracked by Wall St. Rank hold NAMS as of Q3 2025.

  • Algert Global reported no remaining NewAmsterdam Pharma position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 18,140 NewAmsterdam Pharma shares in Q3 2025, an estimated $329K.
  • Algert Global first reported a position in NewAmsterdam Pharma in Q2 2025 and held it in 1 quarter.
  • Algert Global's NewAmsterdam Pharma position peaked at $329K in Q2 2025.
  • 137 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.